Wellgistics Eyes $105M Acquisition

Wellgistics Health has signed a non-binding letter of intent to explore the acquisition of Neuritek Therapeutics in an all-stock deal valued at $105 million. The target, which specializes in innovative therapies for neurological and psychiatric disorders, would allow the group to expand its healthcare platform and strengthen its presence in specialty care. The announcement is broadly positive for WGRX shares, as it points to an ambitious and potentially value-creating acquisition strategy. However, the non-binding nature of the agreement still leaves uncertainty over whether the deal will be completed, its potential dilutive impact, and the market’s ability to endorse this expansion.